AI vs. Offshore: The Real Cost Comparison

Automate intake, eligibility, and PA with AI agents that work in your EMR and billing systems.

Contact us to get started

Create a free account to automate medical coding. Just upload a chart and get codes.

Create Free Account

CMS National Coverage Determination (NCD)

CMS Anti-Inhibitor Coagulant Complex (AICC) Form

Effective Date

01/01/2066

Last Reviewed

NA

Original Document

  Reference


Related policies from health plans

Anti-Inhibitor Coagulant Complex (AICC)
Adefovir Dipivoxil (Hepsera) (PG081)
Adefovir Dipivoxil (Hepsera) (PG081)
Apretude (cabotegravir extended-release injectable suspension) (PG158)
Apretude (cabotegravir extended-release injectable suspension) (PG158)
Antidiabetic Agents - Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & SGLT2 Antidiabetic Combinations (PG154)
Antidiabetic Agents - Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & SGLT2 Antidiabetic Combinations (PG154)
Allergen Immunotherapy
Allergen Immunotherapy

Anti-inhibitor coagulant complex, AICC, is a drug used to treat hemophilia in patients with factor VIII inhibitor antibodies. AICC has been shown to be safe and effective and has Medicare coverage when furnished to patients with hemophilia A and inhibitor antibodies to factor VIII who have major bleeding episodes and who fail to respond to other, less expensive therapies.